6L8 Stock Chart & Stats
€30.80
€4.40(16.67%)
At close: 4:00 PM EDT
€30.80
€4.40(16.67%)
Day’s Range― - ―
52-Week Range€10.80 - €42.80
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
€2.94B
Enterprise Value€1.82K
Total Cash (Recent Filing)€101.62M
Total Debt (Recent Filing)€6.77M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 16, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding71,322,610
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.82Price Target Upside26.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.05
Revenue Forecast (FY)€2.06M
Bulls Say, Bears Say
Bulls Say
Strong Clinical Efficacy And Safety SignalsThe feasibility results support nsPFA’s potential to deliver durable atrial-fibrillation outcomes with limited adverse events. If replicated in pivotal studies, this evidence could strengthen physician adoption, regulatory prospects and Pulse’s competitive position.
Accelerated Pivotal Enrollment And Expanding Clinical PipelineFaster enrollment reduces execution risk and may advance regulatory milestones for the cardiac catheter. Progress across the surgical clamp, thyroid and other studies also broadens the platform’s potential indications and future commercial opportunities.
Improved Liquidity And Low Balance-sheet LeverageThe stronger cash position and limited debt provide financial flexibility to fund pivotal trials and regulatory work without substantial interest burden. This supports continued execution, although the runway remains dependent on spending discipline and financing access.
Bears Say
Very Small Commercial Revenue Base And Deep LossesPulse remains in limited commercialization, so current revenue does not meaningfully offset development costs. Negative gross profit and large operating losses indicate that sustainable margins and profitability depend on successful product launches and significant future procedure adoption.
Heavy Cash Burn And Dependence On Equity FinancingLarge cash outflows are translating directly into ongoing financing needs while clinical programs advance. ATM funding extends liquidity but may dilute shareholders, and additional capital could be required before the business generates enough recurring consumables revenue.
Regulatory Timing Remains Dependent On Long-term Clinical Follow-upRapid enrollment does not eliminate the need to observe patients through required follow-up periods. Delays, incomplete data or regulatory requests could postpone approval and commercialization, extending the period of high spending before meaningful product revenue develops.
Pulse Biosciences News
6L8 FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was €10.80 and its highest was €42.80 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is €2.94B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 80 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -€0.245 earnings per share for the quarter, beating the consensus estimate of -€0.268 by €0.022.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 71,322,610 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -€0.245 in its last earnings report, beating expectations of -€0.268. Following the earnings report the stock price went down -1.227%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in DE:6L8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€38.82 (26.03% Upside)
€38.82 (26.03% Upside)
Blogger Sentiment
Bullish
DE:6L8 Sentiment 80%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
6L8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all DE:6L8 earnings summaries6L8 Stock 12 Month Forecast
Average Price Target
€38.82
▲(26.03% Upside)